Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial

Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial

Bibliographic Details
Main Authors: Grégoire Stalder, Madeleine Suffiotti, Amandine Segot, Alessandra Noto, Giuseppe Pantaleo, Olivier Spertini, Michel Obeid
Format: Article
Language:English
Published: Ferrata Storti Foundation 2022-09-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/10794

Internet

https://haematologica.org/article/view/10794

Similar Items